NPI: 1114974029 · LENOIR, NC 28645 · General Acute Care Hospital · NPI assigned 05/27/2006
Authorized official SHADOWENS, KAREN controls 20+ related entities in our dataset. Read more
| Authorized Official | SHADOWENS, KAREN (CFO) |
| NPI Enumeration Date | 05/27/2006 |
Other providers sharing the same authorized official: SHADOWENS, KAREN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 112,426 | $2.59M |
| 2019 | 119,471 | $2.79M |
| 2020 | 83,015 | $1.80M |
| 2021 | 115,351 | $4.15M |
| 2022 | 129,686 | $5.70M |
| 2023 | 133,259 | $6.06M |
| 2024 | 125,854 | $5.73M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 287,764 | 261,650 | $7.57M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 27,872 | 26,210 | $5.36M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 16,938 | 15,520 | $3.52M |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 39,936 | 37,729 | $2.61M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 12,814 | 12,183 | $1.13M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4,853 | 4,287 | $1.07M |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 22,716 | 21,689 | $931K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 42,066 | 40,731 | $653K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 870 | 806 | $628K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 25,717 | 17,703 | $524K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3,648 | 3,447 | $431K |
| 70450 | Computed tomography, head or brain; without contrast material | 1,143 | 1,044 | $306K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4,690 | 4,235 | $249K |
| 36902 | 1,057 | 1,003 | $245K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2,744 | 2,421 | $219K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1,316 | 1,234 | $210K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 4,504 | 3,886 | $210K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 29,446 | 26,527 | $207K |
| 87081 | 27,324 | 26,430 | $205K | |
| J3490 | Unclassified drugs | 48,167 | 22,576 | $191K |
| 92552 | 6,053 | 5,806 | $185K | |
| 80053 | Comprehensive metabolic panel | 21,710 | 19,535 | $166K |
| 96127 | 19,987 | 19,299 | $152K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 2,237 | 1,967 | $150K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3,049 | 2,689 | $108K |
| 71046 | Radiologic examination, chest; 2 views | 2,268 | 2,119 | $83K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 614 | 551 | $77K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1,312 | 1,174 | $74K |
| 36415 | Collection of venous blood by venipuncture | 34,738 | 30,900 | $67K |
| 90837 | Psychotherapy, 53 minutes with patient | 1,578 | 1,015 | $60K |
| 81001 | 16,343 | 14,878 | $52K | |
| 87634 | 412 | 405 | $46K | |
| 87807 | 2,498 | 2,422 | $45K | |
| 71045 | Radiologic examination, chest; single view | 1,989 | 1,730 | $38K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 446 | 438 | $38K |
| 73630 | 2,312 | 1,948 | $35K | |
| 96161 | 5,257 | 4,989 | $35K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 4,525 | 4,111 | $34K |
| 84484 | 4,616 | 3,577 | $33K | |
| 99152 | 1,437 | 1,337 | $31K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 3,712 | 3,386 | $31K |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 1,245 | 1,147 | $30K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 369 | 343 | $29K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 954 | 919 | $27K |
| 84443 | Thyroid stimulating hormone (TSH) | 1,741 | 1,640 | $27K |
| 80076 | 2,504 | 2,161 | $26K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 2,952 | 2,672 | $26K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 3,125 | 2,923 | $25K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 525 | 457 | $25K |
| 81025 | 2,836 | 2,629 | $23K | |
| J7030 | Infusion, normal saline solution , 1000 cc | 1,817 | 1,590 | $23K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 450 | 311 | $23K |
| 0002A | 418 | 372 | $22K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 462 | 147 | $21K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 307 | 287 | $20K |
| 83690 | 3,130 | 2,816 | $20K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 675 | 571 | $19K |
| 83550 | 1,580 | 1,488 | $19K | |
| 0001A | 385 | 328 | $18K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 16 | 16 | $17K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 44 | 39 | $16K |
| 82728 | 817 | 775 | $16K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 227 | 207 | $16K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1,673 | 1,598 | $16K |
| 80061 | Lipid panel | 1,051 | 996 | $15K |
| 83540 | 1,584 | 1,491 | $14K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 872 | 775 | $12K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 14 | 13 | $11K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 14 | 14 | $10K |
| 97010 | 281 | 92 | $9K | |
| 83735 | 1,495 | 1,361 | $9K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 49 | 49 | $9K |
| J7050 | Infusion, normal saline solution, 250 cc | 2,144 | 1,511 | $9K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 28 | 27 | $8K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 26 | 26 | $8K |
| 82607 | 452 | 439 | $8K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 48 | 45 | $8K |
| C1769 | Guide wire | 1,434 | 1,300 | $8K |
| 92567 | 1,039 | 963 | $8K | |
| 83655 | 420 | 393 | $7K | |
| J1644 | Injection, heparin sodium, per 1000 units | 3,694 | 2,434 | $7K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 1,399 | 1,277 | $6K |
| J0690 | Injection, cefazolin sodium, 500 mg | 2,342 | 2,029 | $6K |
| J2704 | Injection, propofol, 10 mg | 1,446 | 1,144 | $6K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 299 | 265 | $6K |
| 11750 | 40 | 38 | $6K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 3,192 | 2,661 | $6K |
| 81003 | 2,204 | 2,045 | $5K | |
| 93017 | 138 | 133 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 1,495 | 1,366 | $5K |
| 99243 | 201 | 191 | $5K | |
| 76801 | 146 | 112 | $5K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1,620 | 1,440 | $5K |
| 99406 | 776 | 726 | $4K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 106 | 104 | $4K |
| 83880 | 178 | 159 | $4K | |
| 76830 | Ultrasound, transvaginal | 56 | 54 | $4K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 42 | 41 | $4K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 103 | 40 | $3K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 2,775 | 2,481 | $3K |
| 85018 | 1,394 | 1,346 | $3K | |
| 0031A | 74 | 73 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 150 | 146 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 816 | 608 | $3K |
| 11730 | 62 | 52 | $3K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 75 | 75 | $3K |
| 84439 | 266 | 254 | $3K | |
| 86300 | 106 | 86 | $3K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 80 | 55 | $3K |
| 93923 | 29 | 15 | $3K | |
| 73130 | 38 | 38 | $2K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 48 | 48 | $2K |
| 72110 | 66 | 66 | $2K | |
| 73030 | 42 | 38 | $2K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 504 | 441 | $1K |
| 0072A | 26 | 25 | $1K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 264 | 241 | $1K |
| 82378 | 47 | 39 | $1K | |
| 85610 | 250 | 229 | $1K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 41 | 40 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 39 | 38 | $1K |
| 85027 | 163 | 160 | $1K | |
| 51798 | 166 | 149 | $993.68 | |
| C1760 | Closure device, vascular (implantable/insertable) | 13 | 12 | $977.40 |
| 82962 | 1,470 | 1,105 | $966.38 | |
| 90834 | Psychotherapy, 45 minutes with patient | 37 | 25 | $955.76 |
| 0004A | 15 | 14 | $927.87 | |
| 0012A | 15 | 15 | $910.00 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 97 | 95 | $905.74 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 36 | 36 | $875.00 |
| 86671 | 35 | 27 | $871.80 | |
| 90791 | Psychiatric diagnostic evaluation | 32 | 25 | $769.76 |
| J8597 | Antiemetic drug, oral, not otherwise specified | 175 | 157 | $664.09 |
| 0071A | 17 | 13 | $644.22 | |
| 20610 | 28 | 25 | $565.76 | |
| 83615 | 63 | 55 | $521.27 | |
| 84132 | 729 | 614 | $511.09 | |
| 84480 | 25 | 25 | $453.19 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 117 | 101 | $443.57 |
| 87420 | 31 | 31 | $442.68 | |
| 0011A | 22 | 22 | $429.34 | |
| 83605 | 40 | 38 | $412.61 | |
| 87040 | 16 | 14 | $411.76 | |
| 92579 | 43 | 38 | $408.16 | |
| 73610 | 16 | 14 | $407.30 | |
| J2785 | Injection, regadenoson, 0.1 mg | 37 | 37 | $390.81 |
| 94664 | 12 | 12 | $377.88 | |
| 94642 | 12 | 12 | $377.88 | |
| 87186 | 49 | 49 | $373.74 | |
| 85055 | 15 | 14 | $365.66 | |
| 92553 | 13 | 12 | $358.92 | |
| 87070 | 92 | 79 | $346.60 | |
| 31575 | 15 | 13 | $342.72 | |
| 84702 | 30 | 27 | $283.95 | |
| 85730 | 81 | 70 | $282.08 | |
| 86140 | 39 | 39 | $278.62 | |
| 88141 | 14 | 12 | $278.26 | |
| 87077 | 38 | 38 | $258.50 | |
| 58300 | 13 | 12 | $257.92 | |
| 90715 | 13 | 12 | $241.62 | |
| 81002 | 142 | 138 | $233.95 | |
| 0003A | 22 | 14 | $210.85 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 271 | 235 | $199.43 |
| 86036 | 27 | 27 | $185.05 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 17 | 15 | $184.81 |
| 87205 | 94 | 81 | $171.54 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 57 | 53 | $168.46 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 88 | 70 | $161.42 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 62 | 51 | $160.43 |
| J1170 | Injection, hydromorphone, up to 4 mg | 31 | 26 | $158.26 |
| 76937 | 47 | 42 | $153.08 | |
| 90656 | 14 | 13 | $135.57 | |
| A9270 | Non-covered item or service | 3,467 | 1,620 | $113.54 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 13 | 13 | $94.89 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 30 | 24 | $91.49 |
| 82550 | 80 | 66 | $89.21 | |
| J1790 | Injection, droperidol, up to 5 mg | 12 | 12 | $65.31 |
| 99153 | Mod sedat endo service >5yrs | 17 | 15 | $64.71 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 14 | 14 | $59.22 |
| 90686 | 30 | 30 | $36.53 | |
| 82948 | 14 | 13 | $11.56 | |
| 91300 | 1,188 | 966 | $3.25 | |
| 91307 | 75 | 65 | $1.30 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 28 | 23 | $0.90 |
| 36416 | 414 | 394 | $0.00 | |
| 91303 | 74 | 73 | $0.00 | |
| 91301 | 45 | 43 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 18 | 18 | $0.00 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 247 | 131 | $0.00 |